Cadazolid does not promote intestinal colonization of vancomycin-resistant enterococci in mice

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 628-631

  Seiler, Peter ^a   Enderlin Paput, Michel ^a   Pfaff, Philippe ^a   Weiss, Maria ^a   Ritz, Daniel ^a   Clozel, Martine ^a   Locher, Hans H ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CADAZOLID; FIDAXOMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; EFFECTIVE DOSE (PHARMACOLOGY); IN VITRO STUDY; INTESTINE FLORA; INTRINSIC ACTIVITY; MORTALITY RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; DIARRHEA; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GROWTH, DEVELOPMENT AND AGING; INTESTINE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INTESTINES; METRONIDAZOLE; MICE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84957927021     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01923-15     Document Type: Article

References (22)

1. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403-2406. http://dx.doi.org/10.1128/AAC.00090-08.
2. Lin MY, Hayden MK. 2010. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: recognition and prevention in intensive care units. Crit Care Med 38:S335-44. http://dx.doi.org/10.1097/CCM.0b013e3181e6ab12.
3. Orsi GB, Ciorba V. 2013. Vancomycin resistant enterococci healthcare associated infections. Ann Ig 25:485-492. http://dx.doi.org/10.7416/ai.2013.1948.
4. Tacconelli E, Cataldo MA. 2008. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents 31:99-106. http://dx.doi.org/10.1016/j.ijantimicag.2007.08.026.
5. Zirakzadeh A, Patel R. 2006. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 81:529-536. http://dx.doi.org/10.4065/81.4.529.
6. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. 2002. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 162:2223-2228. http://dx.doi.org/10.1001/archinte.162.19.2223.
7. Hautemaniere A, Hunter PR, Diguio N, Albuisson E, Hartemann P. 2009. A prospective study of the impact of colonization following hospital admission by glycopeptide-resistant Enterococci on mortality during a hospital outbreak. Am J Infect Control 37:746-752. http://dx.doi.org/10.1016/j.ajic.2009.02.007.
8. Sakka V, Tsiodras S, Galani L, Antoniadou A, Souli M, Galani I, Pantelaki M, Siafakas N, Zerva L, Giamarellou H. 2008. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect 14:14-21. http://dx.doi.org/10.1111/j.1469-0691.2007.01840.x.
9. Salgado CD. 2008. The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients. Am J Infect Control 36:S175.e5-8. http://dx.doi.org/10.1016/j.ajic.2008.10.010.
10. Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W. 2014. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58:892-900. http://dx.doi.org/10.1128/AAC.01830-13.
11. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
12. Locher HH, Pfaff P, Schroeder S, Specklin JL, Hubschwerlen C, Keck W. 2012. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic with potent activity against Clostridium difficile: in vitro antibacterial activity and propensity for resistance development. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA. http://www.icaac.org/.
13. Rashid MU, Lozano HM, Weintraub A, Nord CE. 2013. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 20:32-35. http://dx.doi.org/10.1016/j.anaerobe.2013.02.003.
14. Chilton CH, Crowther GS, Baines SD, Todhunter SL, Freeman J, Locher HH, Athanasiou A, Wilcox MH. 2014. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 69:697-705. http://dx.doi.org/10.1093/jac/dkt411.
15. Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA. 2015. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 59:6266-6273. http://dx.doi.org/10.1128/AAC.00504-15.
16. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, Viale A, Socci ND, van den Brink MR, Kamboj M, Pamer EG. 2010. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 120:4332-4341. http://dx.doi.org/10.1172/JCI43918.
17. Deshpande A, Hurless KN, Cadnum JL, Chesnel L, Chan L, Kundrapu S, Donskey CJ. 2014. Effect of surotomycin, a novel lipopeptide antibiotic, on disruption of the microbiome and susceptibitility to colonization with enteric pathogens, abstr F-235. Abstr 54th Intersci Conf Antimicrob Agents Chemother.
18. Hurless K, Cadnum JL, Chesnel L, Polinkovsky A, Deshpande A, Donskey CJ. 2013. Effect of surotomycin, a novel cyclic lipopeptide antibiotic, on intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice, abstr F-628. Abstr 53rd Intersci Conf Antimicrob Agents Chemother.
19. Jump RL, Nerandzic MM, Pultz MJ, Donskey CJ. 2011. Effect of antibiotics used for treatment of Clostridium difficile infection in intestinal colonization with vancomycin-resistant Enterococci and KIebsiella pneumoniae in mice, abstr B-1190. Abstr 51st Intersci Conf Antimicrob Agents Chemother.
20. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S121-S126. http://dx.doi.org/10.1093/cid/cis440.
21. Sethi AK, Al-Nassir WN, Nerandzic MM, Donskey CJ. 2009. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 30:13-17. http://dx.doi.org/10.1086/592710.
22. Nerandzic MM, Donskey CJ. 2011. Emergence of fidaxomicin-resistant vancomycin-resistant enterococci in mice treated with fidaxomicin, abstr K-1476. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago IL.